Novogen Granted U.S. Patent Covering Phenoxodiol for Cancer Treatment
November 19 2003 - 9:25AM
PR Newswire (US)
Novogen Granted U.S. Patent Covering Phenoxodiol for Cancer
Treatment STAMFORD, Conn., Nov. 19 /PRNewswire-FirstCall/ --
Pharmaceutical company Novogen , has been granted the U.S. patent
covering methods for treating all benign and malignant cancers with
the anti-cancer drug phenoxodiol, including ovarian cancer, breast
cancer, prostate cancer and cervical cancer. Phenoxodiol is
currently in phase II human clinical trials in the U.S. and
Australia, and the rights to commercialize phenoxodiol have been
licensed to the Novogen majority-owned U.S. company Marshall
Edwards, Inc. Managing Director of Novogen, Mr. Christopher
Naughton, said the latest patent joined a suite of existing
protection which consolidated and further secured Novogen's
intellectual property position. Novogen has a leading position in
the research and development of drugs derived from its phenolic
technology platform. The Company manages its international research
and development programs using the expertise and clinical research
capabilities of universities and hospitals in the U.S., Australia
and other key international locations. The oncology compound
phenoxodiol is being developed by the Company's listed subsidiary
Marshall Edwards, Inc. (LSE-AIM: MSH). More information on
phenoxodiol and on the Novogen group of companies can be found at
http://www.marshalledwardsinc.com/ and http://www.novogen.com/ .
Under U.S. law, a new drug cannot be marketed until it has been
investigated in clinical trials. After the results of these trials
are submitted in a new drug application to the FDA, the FDA must
approve the drug as safe and effective before marketing can take
place. Statements herein that are not descriptions of historical
facts are forward-looking and subject to risk and uncertainties.
Actual results could differ materially from those currently
anticipated due to a number of factors, including those set forth
in the Company's Securities and Exchange Commission filings under
"Risk Factors," including risks relating to the early stage of
products under development; uncertainties relating to clinical
trials; dependence on third parties; future capital needs; and
risks relating to the commercialization, if any, of the Company's
proposed products (such as marketing, safety, regulatory, patent,
product liability, supply, competition and other risks).
DATASOURCE: Novogen Limited CONTACT: Warren Lancaster of Novogen,
+1-203-327-1188 Web site: http://www.novogen.com/
http://www.marshalledwardsinc.com/
Copyright
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jul 2023 to Jul 2024